Drug Profile
JNJ 41443532
Alternative Names: JNJ-41443532Latest Information Update: 03 Mar 2016
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Janssen Research & Development
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action CCR2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 18 Aug 2015 No recent reports on development identified - Phase-I for Type-2 diabetes mellitus (In volunteers) in Belgium (PO)
- 10 Dec 2010 Phase-II clinical trials in Type-2 diabetes mellitus in USA (PO)
- 29 Apr 2010 Phase-I clinical trials in Type-2 diabetes mellitus in Belgium (PO)